Zumutor is a leading Immuno-Oncology company in the space of targeted NK cell therapeutics. We have two proprietary Antibody Engineering Platforms to develop novel immunotherapies that target innate immunity and regulate the tumor microenvironment.
Formed in 2013, we are headquartered at CIC Cambridge Campus, 1 Broadway, Cambridge, MA, USA and an ISO 9001:2015 laboratory in Bangalore, India.
Our key successes include global licensing of a biologic product for the treatment of breast cancer and multiple partnerships for development programs using our technology platforms.
“Combination of Zumutor’s platforms lead to novel and improved monoclonal antibody therapeutics”
Discover The Future
We attract, retain and nurture scientific talent who shares our dream of pushing the boundaries of therapeutic research and development.